An observational study in Urolithiasis, Calcium Oxalate, sponsored by Hisar Intercontinental Hospital. Completed. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-05-28.
Sponsored by Hisar Intercontinental Hospital · Observational
This retrospective observational study investigates the metabolic abnormalities associated with different types of kidney stones by analyzing their composition. The study includes adult patients diagnosed with urolithiasis, whose stone samples were analyzed using Fourier Transform Infrared (FTIR) spectroscopy. Clinical, biochemical, and 24-hour urine metabolic parameters were compared between first-time and recurrent stone formers, and among subtypes of calcium oxalate stones (monohydrate vs. dihydrate). The goal is to identify metabolic risk factors that contribute to stone formation and recurrence, and to provide insights for individualized prevention strategies.
This retrospective study aims to evaluate the metabolic characteristics of patients with urolithiasis based on kidney stone composition. Data were collected from patients treated for kidney stones between January 2010 and December 2024 at a tertiary urology center. Stone analysis was performed using FTIR spectroscopy, classifying stones into subtypes including calcium oxalate monohydrate (COM), calcium oxalate dihydrate (COD), uric acid, and mixed types.
Serum levels of calcium, phosphorus, uric acid, creatinine, and parathyroid hormone (PTH), along with 24-hour urine values (calcium, oxalate, citrate, uric acid, volume, and pH), were recorded. The study primarily compares metabolic differences between:
First-time vs. recurrent stone formers
COM vs. COD stone subtypes
Findings from this study are expected to improve understanding of metabolic risk factors and contribute to the development of tailored metabolic evaluations and dietary or pharmacological preventive strategies for recurrent stone formers.
253 studies on the registry are indexed under Urolithiasis; 67 are open to participants now.
This study's enrollment of 506 is above the median of 150 across 65 observational studies indexed under Urolithiasis.
Browse Urolithiasis studies →Hisar Intercontinental Hospital is the lead sponsor of 19 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
This study included 506 patients who presented with nephrolithiasis and underwent metabolic evaluation of stone composition. Data were collected retrospectively from medical records at Hisar Intercontinental Hospital between 2010 and 2024.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Adult patients who presented with their first episode of kidney stone disease. These patients underwent stone composition analysis via FTIR spectroscopy and metabolic evaluation including serum and 24-hour urine testing to identify risk factors for initial stone formation.
Other: Metabolik taş analizi ile retrospektif gözlem
Patients with a documented history of recurrent kidney stone episodes. These individuals were evaluated to assess differences in metabolic profiles and stone composition compared to first-time stone formers, with the aim of identifying predictors of recurrence and optimizing preventive strategies.
Other: Metabolik taş analizi ile retrospektif gözlem
This study did not involve an active intervention. It retrospectively analyzed medical records of 506 patients who underwent compositional analysis of kidney stones to identify metabolic abnormalities. The aim was to evaluate stone composition in relation to metabolic parameters such as serum and 24-hour urine values, without modifying patient treatment.
Also known as: Böbrek taşı kompozisyonu değerlendirmesi Retrospektif metabolik değerlendirme
Kalsiyum oksalat taşı tipine göre serum ve 24 saatlik idrar parametrelerinin dağılımı Zaman Çerçevesi (Time Frame): 01 Ocak 2010 - 31 Aralık 2024 tarihleri arasında toplanan hasta verileri
FTIR spektroskopisi ile taş bileşimi belirlenen hastalar arasında, kalsiyum oksalat monohidrat (COM) ve dihidrat (COD) taşı olan bireylerin metabolik parametreleri (serum kalsiyum, fosfor, magnezyum, parathormon; 24 saatlik idrarla kalsiyum, oksalat, sitrat, pH, Na, ürik asit vb.) retrospektif olarak analiz edilmiştir.
Time frame: January 2010 and December 2024
No study locations are listed for this record.
Plan to share: Yes — De-identified individual participant data (IPD) to be shared include stone composition types (e.g., calcium oxalate monohydrate vs dihydrate), serum metabolic parameters (e.g., calcium, phosphorus, PTH), and 24-hour urine findings (e.g., oxalate, citrate, pH, sodium, uric acid).
Supporting information: Study protocol, Statistical analysis plan, Analytic code
Time frame: Data will be made available 6 months after publication of the main study results and will remain accessible for a period of 36 months upon request.
Access criteria: Qualified researchers affiliated with academic or healthcare institutions may request access to the de-identified IPD for secondary analysis or meta-analysis. Requests should be submitted to the corresponding author with a detailed research proposal. Data access will be granted following review and under a data-sharing agreement.
No publications or documents are linked to this record.
Ran from Jan 2010 to primary completion in Dec 2024, 179 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Hisar Intercontinental Hospital